A randomized, double‐blind, single‐dose, three‐arm, parallel group study to determine pharmacokinetic similarity of ABP 959 and eculizumab (Soliris(®)) in healthy male subjects

OBJECTIVES: ABP 959 is a proposed biosimilar to eculizumab, a monoclonal antibody targeting the human C5 complement protein. The objective of this randomized, double‐blind, three‐arm, study was to demonstrate pharmacokinetic (PK) and pharmacodynamic (PD) similarity of ABP 959 relative to the eculizu...

Descripción completa

Detalles Bibliográficos
Autores principales: Chow, Vincent, Pan, Jean, Chien, David, Mytych, Daniel T., Hanes, Vladimir
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7384155/
https://www.ncbi.nlm.nih.gov/pubmed/32196749
http://dx.doi.org/10.1111/ejh.13411

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7384155/
https://www.ncbi.nlm.nih.gov/pubmed/32196749
http://dx.doi.org/10.1111/ejh.13411

Ejemplares similares